Using Smartwatches and Blood Tests to Track Hidden Multiple Sclerosis Progression

This research study is testing whether smartwatches and blood tests can better detect hidden disease progression in people with multiple sclerosis who are already taking monoclonal antibodies like Natalizumab, Ofatumumab, or Ocrelizumab. The study aims to catch disease changes early — changes that happen without obvious relapses. By combining smartwatch data, blood measurements, and imaging, researchers hope to find better warning signs of disease activity.

Many people with multiple sclerosis on modern medications still experience gradual disability even when they're not having obvious symptom flare-ups. This 'silent' disease progression is hard to detect with standard office visits alone. This study exists to find new, sensitive tools — including wearable technology — that can catch these hidden changes earlier, so doctors can adjust treatment sooner if needed.